11 Results for "

HPK1-IN-4

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "HPK1-IN-4" in MCE Product Catalog:

Cat. No.: HY-138569
CAS No.: 2739844-28-9
Purity:  99.42%
Target:  

MAP4K

Research Areas:  

Cancer

HPK1-IN-4 (comp 22) is a HPK1 (MAPK41) inhibitor (IC50 of 0.061 nM) as preclinical immunoresearch tool compound .
loading...
    loading...
Cat. No.: HY-138568
CAS No.: 2739844-34-7
Purity:  98.61%
Target:  

MAP4K

Research Areas:  

Inflammation/Immunology

HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC50 of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC50 of 108 nM in human peripheral blood mononuclear cells (PBMCs) .
loading...
    loading...
Cat. No.: HY-170443
CAS No.: 2736458-30-1
Target:  

MAP4K

Research Areas:  

Cancer

PF-07265028 is a selective hematopoietic progenitor kinase 1 (HPK1/MAP4K1). PF-07265028 can be used in the research of cancer. PF-07265028 shows very potent cellular activity as measured by pSLP76 IC50 (17 nM) .
loading...
    loading...
Cat. No.: HY-174357
Research Areas:  

Cancer

HPK1 ligand 3-dimethylph tetrahydropyridine is a Target Protein Ligand-Linker Conjugate. HPK1 ligand 3-dimethylph tetrahydropyridine can be used to synthesize PROTAC HPK1 Degrader-4 (HY-174135) .
loading...
    loading...
Cat. No.: HY-174135
Research Areas:  

Cancer

PROTAC HPK1 Degrader-4 is an orally active HPK1 PROTAC degrader and immune activator, with DC50 values of 3.16 nM and 72.59 nM in Jurkat cells and PBMCs, respectively. PROTAC HPK1 Degrader-4 induces degradation via the ubiquitin-proteasome system, downregulates the HPK1-SLP76 signaling pathway, reduces the phosphorylation level of SLP76 (S376), and promotes immune activation. PROTAC HPK1 Degrader-4 can be used in the research of colorectal cancer and B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-143868
CAS No.: 2268794-52-9
Target:  

MAP4K

Research Areas:  

Cancer

HPK1-IN-27 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-27 has the potential for the research of cancer diseases (extracted from patent WO2019016071A1, compound 38) .
loading...
    loading...
Cat. No.: HY-143871
CAS No.: 2700292-56-2
Target:  

MAP4K

Research Areas:  

Cancer

HPK1-IN-30 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-30 has the potential for the research of cancer diseases (extracted from patent WO2021175271A1, compound 3) .
loading...
    loading...
Cat. No.: HY-174355
Research Areas:  

Cancer

HPK1 ligand 3 is a ligand for target protein for PROTAC that can be used to synthesize PROTAC HPK1 Degrader-4 (HY-174135) .
loading...
    loading...
Cat. No.: HY-174356
CAS No.: 2816115-88-3
Target:  

PROTAC Linkers

Research Areas:  

Others

Boc-(2,6-DMP)-THP-Bpin is a PROTAC linker that can be used in the synthesis of PROTAC HPK1 Degrader-4 (HY-174135). PROTAC HPK1 Degrader-4 is a selective and orally active PROTAC HPK1 degrader with a DC50 of 3.16 nM .
loading...
    loading...
Cat. No.: HY-175549
Research Areas:  

Cancer

HPK1 ligand 4 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as PROTAC HPK1 Degrader-5 (HY-175547). PROTAC HPK1 Degrader-5 is a potent and orally active HPK1 PROTAC degrader with anti-tumor activity .
loading...
    loading...
Cat. No.: HY-187930
CAS No.: 2965385-11-7
Target:  

MAP4K

Research Areas:  

Cancer

HPK1-IN-72 is an orally active and selective HPK1/MAP4K1 inhibitor with an IC50 of 52.4 nM against human targets. HPK1-IN-72 inhibits HPK1 activation, blocks the negative regulation of T cell receptor signaling, restores T cell receptor signal transduction and enhances T cell function. HPK1-IN-72 suppresses tumor growth, exhibits potent single-agent anti-tumor efficacy, and also produces synergistic effects with anti-PD-1 antibodies or anti-PD-L1/IL-15 immunocytokine prodrugs. HPK1-IN-72 can be used in research related to breast cancer, colorectal cancer and prostate cancer .
loading...
    loading...
  • 1